Share Price and Basic Stock Data
Last Updated: December 10, 2025, 11:46 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hindustan Agrigenetics Ltd operates in the floriculture sector, a niche that has shown potential for growth in India. As of September 2025, the company’s market capitalization stood at ₹23.3 Cr, with its share price at ₹53.0. The revenue figures tell a rather erratic story; sales have fluctuated significantly over the past few quarters. In June 2023, the company recorded sales of ₹0.04 Cr, which was consistent with the previous quarter but starkly contrasted with the zero sales reported in September 2023. This inconsistency raises questions about the company’s operational stability. Over the past several years, revenue has remained relatively stagnant, with the highest recorded annual sales being ₹0.19 Cr in FY 2020. The trailing twelve months (TTM) revenue is reported at ₹0.07 Cr, reflecting a steady state but lacking momentum. This trend suggests that while the company is engaged in a potentially lucrative industry, it may be struggling to capitalize on market opportunities effectively.
Profitability and Efficiency Metrics
When we delve into profitability, Hindustan Agrigenetics presents a challenging picture. The company has recorded net profits that are inconsistent at best, with a net profit of ₹0.04 Cr reported for the TTM. However, this figure is overshadowed by the stark operational losses reflected in the operating profit margin (OPM), which stands at an alarming -250.00%. This negative margin indicates that the company is spending significantly more than it earns from its core operations, a concern for any investor. The return on equity (ROE) and return on capital employed (ROCE) metrics also raise red flags, at 3.61% and 3.53%, respectively, suggesting that the company is not utilizing its equity and capital effectively to generate returns. Overall, the profitability metrics appear stretched, suggesting a pressing need for operational improvement and cost efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hindustan Agrigenetics reveals a cautious financial stance, particularly with no reported borrowings, which is a positive sign in terms of debt management. As of September 2025, the company holds reserves of ₹8.21 Cr, indicating a potential buffer against operational losses. However, the price-to-book value ratio (P/BV) of 2.49x suggests that the stock may be overvalued compared to its book value of ₹26.95 per share. The interest coverage ratio (ICR) is a troubling -23.78x, which indicates that the company is not generating enough earnings to cover any interest obligations, despite having none at present. This situation highlights a critical risk, as the company might struggle to raise capital or service debt if needed. Investors should note that while the balance sheet has some strengths, the financial ratios indicate underlying vulnerabilities that need addressing.
Shareholding Pattern and Investor Confidence
Investor confidence in Hindustan Agrigenetics appears to be mixed, as reflected in its shareholding pattern. The public holds a substantial 64.71% stake, while promoters own 25.35%. This distribution suggests a strong retail investor presence, which can be a double-edged sword. On one hand, it indicates broad-based interest; on the other hand, the declining promoter stake, which has decreased from 29.42% in March 2023 to the current level, could signal a lack of confidence from those who know the business best. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold a mere 0.43% and 1.08% respectively, implying limited institutional interest in the stock. This lack of institutional backing could be a concern for potential investors, as it may affect the stock’s liquidity and stability in the market.
Outlook, Risks, and Final Insight
The outlook for Hindustan Agrigenetics is clouded by uncertainty and operational challenges. While the floriculture sector has potential, the company’s inability to maintain consistent sales and profitability raises significant risks. Factors such as fluctuating demand, operational inefficiencies, and a lack of institutional support could hinder growth. Moreover, the declining promoter stake might lead to further erosion of investor confidence. For investors considering this stock, it’s crucial to weigh these risks against potential rewards carefully. A turnaround strategy focusing on operational efficiency and better capital management could potentially enhance performance. However, until such a strategy is visible and effective, Hindustan Agrigenetics may remain a speculative investment, appealing primarily to risk-tolerant investors looking for opportunities in niche sectors.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Nagarjuna Agri Tech Ltd | 44.0 Cr. | 47.0 | 83.3/34.8 | 81.5 | 7.73 | 0.00 % | 1.34 % | 1.34 % | 10.0 |
| Hindustan Agrigenetics Ltd | 23.8 Cr. | 54.2 | 103/48.8 | 265 | 0.00 % | 3.53 % | 3.61 % | 10.0 | |
| Elegant Floriculture & Agrotech (India) Ltd | 12.7 Cr. | 4.93 | 11.6/4.38 | 4.11 | 9.94 | 0.00 % | 5.85 % | 5.22 % | 10.0 |
| Industry Average | 0 Cr | 35.38 | 116.87 | 8.84 | 0.00% | 3.57% | 3.39% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 |
| Expenses | 0.33 | 0.05 | 0.11 | 0.12 | 0.03 | 0.07 | -0.06 | 0.01 | 0.01 | 0.00 | 0.24 | 0.69 | 0.14 |
| Operating Profit | -0.29 | -0.05 | -0.08 | -0.12 | 0.01 | -0.07 | 0.09 | -0.01 | 0.03 | 0.00 | -0.21 | -0.69 | -0.10 |
| OPM % | -725.00% | -266.67% | 25.00% | 300.00% | 75.00% | -700.00% | -250.00% | ||||||
| Other Income | 0.09 | 0.14 | 0.15 | 0.03 | 0.14 | 0.16 | 0.15 | 0.15 | 0.02 | 0.15 | 0.24 | 0.18 | 0.51 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | -0.20 | 0.09 | 0.07 | -0.09 | 0.15 | 0.08 | 0.23 | 0.13 | 0.04 | 0.14 | 0.02 | -0.52 | 0.40 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.20 | 0.09 | 0.07 | -0.09 | 0.15 | 0.07 | 0.22 | 0.13 | 0.04 | 0.14 | 0.02 | -0.52 | 0.40 |
| EPS in Rs |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Agrigenetics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Jun 2025, the value is 0.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Mar 2025) to 0.14 Cr., marking a decrease of 0.55 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.10 Cr.. The value appears strong and on an upward trend. It has increased from -0.69 Cr. (Mar 2025) to -0.10 Cr., marking an increase of 0.59 Cr..
- For OPM %, as of Jun 2025, the value is -250.00%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -250.00%, marking a decrease of 250.00%.
- For Other Income, as of Jun 2025, the value is 0.51 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Mar 2025) to 0.51 Cr., marking an increase of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.00. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.19 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.07 |
| Expenses | 0.12 | 0.26 | 0.12 | 0.16 | 0.21 | 0.22 | 0.59 | 0.19 | 0.23 | 0.71 | 0.37 | 1.10 | 1.07 |
| Operating Profit | -0.06 | -0.20 | -0.06 | -0.10 | -0.16 | -0.16 | -0.40 | -0.13 | -0.17 | -0.64 | -0.30 | -1.02 | -1.00 |
| OPM % | -100.00% | -333.33% | -100.00% | -166.67% | -320.00% | -266.67% | -210.53% | -216.67% | -283.33% | -914.29% | -428.57% | -1,275.00% | -1,428.57% |
| Other Income | 0.05 | 0.30 | 0.95 | 0.28 | 0.19 | 0.04 | 0.04 | -0.05 | 0.06 | 10.55 | 0.96 | 0.76 | 1.08 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.03 | 0.09 | 0.88 | 0.17 | 0.02 | -0.13 | -0.37 | -0.18 | -0.11 | 9.91 | 0.60 | -0.31 | 0.04 |
| Tax % | 133.33% | 0.00% | 25.00% | 35.29% | 3,100.00% | -7.69% | -186.49% | -16.67% | -9.09% | 0.50% | 23.33% | 0.00% | |
| Net Profit | -0.07 | 0.09 | 0.66 | 0.11 | -0.59 | -0.12 | 0.33 | -0.15 | -0.10 | 9.86 | 0.47 | -0.31 | 0.04 |
| EPS in Rs | |||||||||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 228.57% | 633.33% | -83.33% | -636.36% | 79.66% | 375.00% | -145.45% | 33.33% | 9960.00% | -95.23% | -165.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.76% | -716.67% | -553.03% | 716.02% | 295.34% | -520.45% | 178.79% | 9926.67% | -10055.23% | -70.72% |
Hindustan Agrigenetics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 3:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
| Reserves | -2.44 | -2.35 | -1.69 | -1.63 | -2.22 | -2.48 | -2.16 | -2.30 | -2.40 | 7.46 | 7.93 | 7.62 | 8.21 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.98 | 1.01 | 0.23 | 0.15 | 0.16 | 0.22 | 0.28 | 0.85 | 6.19 | 0.50 | 0.42 | 0.38 | 0.39 |
| Total Liabilities | 2.94 | 3.06 | 2.94 | 2.92 | 2.34 | 2.14 | 2.52 | 2.95 | 8.19 | 12.36 | 12.75 | 12.40 | 13.00 |
| Fixed Assets | 0.36 | 0.36 | 0.35 | 0.34 | 0.35 | 0.36 | 0.36 | 0.35 | 0.35 | 0.05 | 0.19 | 0.16 | 0.15 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.35 | 1.45 | 1.57 | 1.58 | 1.59 | 1.38 | 0.21 | 1.35 | 1.75 | 0.85 | 1.97 | 3.64 | 3.96 |
| Other Assets | 1.23 | 1.25 | 1.02 | 1.00 | 0.40 | 0.40 | 1.95 | 1.25 | 6.09 | 11.46 | 10.59 | 8.60 | 8.89 |
| Total Assets | 2.94 | 3.06 | 2.94 | 2.92 | 2.34 | 2.14 | 2.52 | 2.95 | 8.19 | 12.36 | 12.75 | 12.40 | 13.00 |
Below is a detailed analysis of the balance sheet data for Hindustan Agrigenetics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.40 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.40 Cr..
- For Reserves, as of Sep 2025, the value is 8.21 Cr.. The value appears strong and on an upward trend. It has increased from 7.62 Cr. (Mar 2025) to 8.21 Cr., marking an increase of 0.59 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.38 Cr. (Mar 2025) to 0.39 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 13.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.40 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 0.60 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.15 Cr.. The value appears to be declining and may need further review. It has decreased from 0.16 Cr. (Mar 2025) to 0.15 Cr., marking a decrease of 0.01 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 3.96 Cr.. The value appears strong and on an upward trend. It has increased from 3.64 Cr. (Mar 2025) to 3.96 Cr., marking an increase of 0.32 Cr..
- For Other Assets, as of Sep 2025, the value is 8.89 Cr.. The value appears strong and on an upward trend. It has increased from 8.60 Cr. (Mar 2025) to 8.89 Cr., marking an increase of 0.29 Cr..
- For Total Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.40 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 0.60 Cr..
Notably, the Reserves (8.21 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | -0.20 | -0.06 | -0.10 | -0.16 | -0.16 | -0.40 | -0.13 | -0.17 | -0.64 | -0.30 | -1.02 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Days | -5,170.83 | -5,353.33 | -730.00 | -243.33 | -365.00 | -608.33 | 883.68 | -4,501.67 | -36,925.83 | -1,668.57 | 730.00 | 11,543.12 |
| ROCE % | -3.51% | -2.00% | 33.61% | 0.00% | 0.81% | -1.95% | -13.46% | -5.99% | -7.80% | 144.88% | 2.07% | -3.53% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| Diluted EPS (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| Cash EPS (Rs.) | -0.61 | 1.15 | 22.41 | -0.21 | -0.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 26.95 | 27.65 | 26.58 | 4.17 | 4.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 27.32 | 28.02 | 26.95 | 4.55 | 4.77 |
| Revenue From Operations / Share (Rs.) | 1.90 | 2.35 | 24.43 | 0.28 | 0.13 |
| PBDIT / Share (Rs.) | -0.59 | 1.46 | 22.52 | -0.24 | -0.40 |
| PBIT / Share (Rs.) | -0.68 | 1.38 | 22.52 | -0.25 | -0.40 |
| PBT / Share (Rs.) | -0.69 | 1.38 | 22.52 | -0.25 | -0.40 |
| Net Profit / Share (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| PBDIT Margin (%) | -31.54 | 62.20 | 92.19 | -85.45 | -288.85 |
| PBIT Margin (%) | -35.83 | 58.64 | 92.17 | -87.40 | -295.28 |
| PBT Margin (%) | -36.76 | 58.64 | 92.17 | -87.40 | -295.28 |
| Net Profit Margin (%) | -36.45 | 45.44 | 91.71 | -76.62 | -238.42 |
| Return on Networth / Equity (%) | -2.57 | 3.85 | 84.29 | -5.28 | -7.52 |
| Return on Capital Employeed (%) | -2.42 | 4.91 | 83.54 | -5.53 | -8.59 |
| Return On Assets (%) | -2.45 | 3.68 | 79.74 | -1.18 | -4.94 |
| Asset Turnover Ratio (%) | 0.06 | 0.08 | 1.05 | 0.02 | 0.02 |
| Current Ratio (X) | 330.73 | 27.72 | 22.40 | 1.11 | 1.92 |
| Quick Ratio (X) | 330.73 | 27.72 | 22.40 | 1.11 | 1.92 |
| Interest Coverage Ratio (X) | -23.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | -26.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 24.41 | 13.01 | -8.02 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 29.16 | 12.59 | -0.74 | 0.00 | 0.00 |
| EV / EBITDA (X) | -92.45 | 20.24 | -0.80 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 35.30 | 21.77 | 0.20 | 0.00 | 0.00 |
| Price / BV (X) | 2.49 | 1.85 | 0.19 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 35.30 | 21.77 | 0.20 | 0.00 | 0.00 |
| EarningsYield | -0.01 | 0.02 | 4.44 | 0.00 | 0.00 |
After reviewing the key financial ratios for Hindustan Agrigenetics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.61. This value is below the healthy minimum of 3. It has decreased from 1.15 (Mar 24) to -0.61, marking a decrease of 1.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 26.95. It has decreased from 27.65 (Mar 24) to 26.95, marking a decrease of 0.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 28.02 (Mar 24) to 27.32, marking a decrease of 0.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1.90. It has decreased from 2.35 (Mar 24) to 1.90, marking a decrease of 0.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.59. This value is below the healthy minimum of 2. It has decreased from 1.46 (Mar 24) to -0.59, marking a decrease of 2.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.68. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.68, marking a decrease of 2.06.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.69, marking a decrease of 2.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 2. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For PBDIT Margin (%), as of Mar 25, the value is -31.54. This value is below the healthy minimum of 10. It has decreased from 62.20 (Mar 24) to -31.54, marking a decrease of 93.74.
- For PBIT Margin (%), as of Mar 25, the value is -35.83. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -35.83, marking a decrease of 94.47.
- For PBT Margin (%), as of Mar 25, the value is -36.76. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -36.76, marking a decrease of 95.40.
- For Net Profit Margin (%), as of Mar 25, the value is -36.45. This value is below the healthy minimum of 5. It has decreased from 45.44 (Mar 24) to -36.45, marking a decrease of 81.89.
- For Return on Networth / Equity (%), as of Mar 25, the value is -2.57. This value is below the healthy minimum of 15. It has decreased from 3.85 (Mar 24) to -2.57, marking a decrease of 6.42.
- For Return on Capital Employeed (%), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 10. It has decreased from 4.91 (Mar 24) to -2.42, marking a decrease of 7.33.
- For Return On Assets (%), as of Mar 25, the value is -2.45. This value is below the healthy minimum of 5. It has decreased from 3.68 (Mar 24) to -2.45, marking a decrease of 6.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.06. It has decreased from 0.08 (Mar 24) to 0.06, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 3. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
- For Quick Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 2. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -23.78. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -23.78, marking a decrease of 23.78.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -26.78. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -26.78, marking a decrease of 26.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 24.41. It has increased from 13.01 (Mar 24) to 24.41, marking an increase of 11.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 29.16. This value exceeds the healthy maximum of 3. It has increased from 12.59 (Mar 24) to 29.16, marking an increase of 16.57.
- For EV / EBITDA (X), as of Mar 25, the value is -92.45. This value is below the healthy minimum of 5. It has decreased from 20.24 (Mar 24) to -92.45, marking a decrease of 112.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 35.30. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 35.30, marking an increase of 13.53.
- For Price / BV (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 1.85 (Mar 24) to 2.49, marking an increase of 0.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 35.30. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 35.30, marking an increase of 13.53.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Agrigenetics Ltd:
- Net Profit Margin: -36.45%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -2.42% (Industry Average ROCE: 3.57%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -2.57% (Industry Average ROE: 3.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -26.78
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 330.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 265 (Industry average Stock P/E: 116.87)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -36.45%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Floriculture | 806, Meghdoot, 94, Nehru Place, New Delhi Delhi 110019 | hindustanagrigenetics@gmail.com http://www.hindustanagrigenetics.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pranav Kapur | Chairman |
| Mr. Pritam Kapur | Director |
| Ms. Chandni Kapur | Director & CFO |
| Ms. Mannu Kohli | Director |
| Mr. Sunny Srivastava | Independent Director |
| Mr. Naren Parsai | Independent Director |
| Mr. Ravi Shankar Kolathur | Independent Director |
FAQ
What is the latest intrinsic value of Hindustan Agrigenetics Ltd?
The latest intrinsic value of Hindustan Agrigenetics Ltd is 0.00. Unfortunately, additional data is unavailable.
What is the Market Cap of Hindustan Agrigenetics Ltd?
The Market Cap of Hindustan Agrigenetics Ltd is 23.8 Cr..
What is the current Stock Price of Hindustan Agrigenetics Ltd as on 13 December 2025?
The current stock price of Hindustan Agrigenetics Ltd as on 13 December 2025 is 54.2.
What is the High / Low of Hindustan Agrigenetics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hindustan Agrigenetics Ltd stocks is 103/48.8.
What is the Stock P/E of Hindustan Agrigenetics Ltd?
The Stock P/E of Hindustan Agrigenetics Ltd is 265.
What is the Book Value of Hindustan Agrigenetics Ltd?
The Book Value of Hindustan Agrigenetics Ltd is .
What is the Dividend Yield of Hindustan Agrigenetics Ltd?
The Dividend Yield of Hindustan Agrigenetics Ltd is 0.00 %.
What is the ROCE of Hindustan Agrigenetics Ltd?
The ROCE of Hindustan Agrigenetics Ltd is 3.53 %.
What is the ROE of Hindustan Agrigenetics Ltd?
The ROE of Hindustan Agrigenetics Ltd is 3.61 %.
What is the Face Value of Hindustan Agrigenetics Ltd?
The Face Value of Hindustan Agrigenetics Ltd is 10.0.